NCT02713373View on ClinicalTrials.gov

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 5, 2016

Primary Completion Date

July 28, 2020

Study Completion Date

July 20, 2021

Conditions
Recurrent Colorectal CarcinomaStage IVA Colorectal CancerStage IVB Colorectal Cancer
Interventions
BIOLOGICAL

Cetuximab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

44106

University Hospitals Seidman Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT02713373 - Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter